It crept into dominance—and by around 2005, it had become the leading lineage worldwide.
In hospital freezers holding samples from the 1970s onward, a quiet evolutionary story was waiting to be read. Researchers from the University of East Anglia, Canada, and Mexico have now traced how Acinetobacter baumannii — one of medicine's most resistant pathogens — did not emerge suddenly as a superbug, but accumulated its defenses in slow, deliberate waves across decades of hospital environments. By reconstructing the bacterium's genetic history across 1,281 samples from six continents, the team has illuminated how resistance is not a crisis that arrives, but one that is continuously being built — and how understanding that process may be the only way to stay ahead of it.
- A pathogen that now threatens vulnerable hospital patients worldwide spent more than thirty years quietly accumulating resistance genes before medicine fully recognized the danger.
- Around 2005, the acquisition of the oxa23 gene marked a tipping point — transforming an already difficult bacterium into one capable of surviving the most powerful antibiotics available.
- Researchers assembled a dataset of 1,281 bacterial genomes spanning five decades and six continents, building an evolutionary map that reveals not just what changed, but when and where each resistance trait took hold.
- The bacterium is not a single evolving strain but at least four distinct lineages, three accumulating resistance gradually and a fourth — newer and rising in frequency — that may be even better adapted to hospital survival.
- Scientists warn that if resistance continues unchecked, infections caused by this pathogen could become entirely untreatable, making the findings a direct call for more disciplined global antibiotic policy.
In hospital storage freezers, bacterial samples dating back to the 1970s sat preserved and largely unread — until a team of researchers from the University of East Anglia, working with colleagues in Canada and Mexico, began thawing and sequencing them. Their goal was to understand how Acinetobacter baumannii, one of medicine's most stubborn pathogens, became a dominant global threat. The answer, it turned out, was not a sudden emergence but a slow, generational accumulation of resistance built quietly in the corridors of hospitals where vulnerable patients lay.
The team assembled 226 historical bacterial samples spanning the 1970s through the early 2000s, extracted their DNA using long-read sequencing technology, and merged this archive with over 1,000 recent genomes from six continents — creating a dataset of 1,281 bacterial chromosomes. From this, they constructed an evolutionary tree that tracked not just how the bacterium changed, but precisely when and where each resistance trait appeared and spread.
The pattern they uncovered resembled less a catastrophe than a relentless march. Resistance accumulated in stages, against multiple antibiotics, over decades. Around 2005, a critical threshold was crossed: the bacterium acquired the oxa23 gene and other genetic elements that effectively supercharged its ability to survive treatment. What had been difficult to kill became dramatically harder.
The research also revealed that A. baumannii is not a single uniform strain. It exists as at least four distinct lineages, three of which show the gradual, step-by-step resistance accumulation seen across the historical record. The fourth is newer, branching off independently and appearing with increasing frequency in recent samples — a potential signal that the pathogen continues to adapt in ways that may outpace current treatments.
Lead researcher Dr. Benjamin Evans was direct about the stakes: this superbug was decades in the making, and it is still evolving. The study's deeper warning is that antimicrobial resistance does not announce itself — it builds in waves, each harder to detect than the last, until the moment a pathogen tips into dominance. The question medicine now faces is whether it can learn from this history quickly enough to stay ahead of what comes next.
In hospital storage freezers across decades, bacterial samples sat waiting to tell a story that nobody had fully read until now. Researchers at the University of East Anglia, working with teams in Canada and Mexico, have spent years thawing and sequencing these frozen remnants—some dating back to the 1970s—to understand how Acinetobacter baumannii, one of medicine's most intractable pathogens, quietly became a global threat.
The bacterium didn't announce itself. It didn't arrive as a superbug. Instead, it evolved in waves, each generation slightly more resistant than the last, accumulating genetic changes in hospital corridors where vulnerable patients lay. By the early 2000s, it had become the dominant strain of its kind worldwide. The question that drove this research was simple but urgent: how did that happen, and what does it tell us about what comes next?
The team assembled 226 samples of the bacterium spanning from the 1970s through the early 2000s. They grew these historical isolates in the lab, extracted their DNA, and sequenced it using long-read technology. Then they merged this historical archive with more than 1,000 recent genomes collected from six continents, creating a dataset of 1,281 bacterial chromosomes. Using computational analysis, they built an evolutionary tree, tracking not just how the bacterium changed over time, but when and where key resistance traits emerged and spread.
What they found was a pattern of adaptation that looked less like a sudden catastrophe and more like a slow, relentless march. The bacterium didn't just develop resistance to one antibiotic—it developed resistance to many, in stages. Around 2005, a critical turning point arrived. The bacterium acquired two major genetic elements, including a gene called oxa23, which confers resistance to some of the most powerful antibiotics available. This acquisition, the researchers found, effectively supercharged the pathogen's ability to survive treatment. What had been difficult to kill became much harder.
But the story grows more complicated. The team discovered that Acinetobacter baumannii is not a single uniform strain evolving along one path. Instead, it exists as at least four distinct groups, each with its own evolutionary trajectory. Three of these groups show a gradual, step-by-step accumulation of resistance over decades—a slow genetic arms race against modern medicine. The fourth group is different. It branched off independently and is now appearing more frequently in recent samples. This newer lineage, researchers warn, may represent a variant that is even better adapted to survive in hospital environments and resist treatment.
Dr. Benjamin Evans, the lead researcher, framed the implications plainly: the superbug didn't just appear. It was decades in the making, and it is still evolving. Understanding how it happened is essential for guiding policy on antibiotic use going forward. Acinetobacter baumannii causes infections that are extremely difficult to treat, particularly in vulnerable patients. If resistance continues to accumulate unchecked, those infections could become untreatable. The research shows that antimicrobial resistance doesn't build overnight—it builds in waves, each one harder to see until the moment when the pathogen tips into dominance. The question now is whether medicine can stay ahead of the next wave.
Notable Quotes
This superbug didn't just appear. It was decades in the making, and it's still evolving.— Dr. Benjamin Evans, University of East Anglia
It crept into dominance—and by around 2005, it had become the leading lineage of A. baumannii worldwide.— Dr. Benjamin Evans, University of East Anglia
The Hearth Conversation Another angle on the story
Why does it matter that this bacterium evolved in waves rather than all at once?
Because waves suggest there were moments when intervention might have made a difference. If we can identify what conditions allowed each wave to build, we might be able to interrupt the next one. A sudden emergence would be almost random—bad luck. Waves suggest a pattern we can study and potentially disrupt.
The samples go back to the 1970s. Why did it take until now to understand what was happening?
The technology didn't exist before. You need to read the entire genetic code of hundreds of bacteria and compare them across decades. That's only become possible in the last few years. We had the samples all along. We just couldn't read them until now.
This fourth group that's rising in frequency—what makes it different?
We don't know yet, exactly. That's what's worrying. It branched off on its own evolutionary path and now it's appearing more often in recent samples. It might be better at surviving in hospitals, or better at resisting antibiotics, or both. The point is it's new enough that we don't fully understand it yet.
If hospitals had used antibiotics differently in the 1980s or 1990s, could they have stopped this?
Possibly. The research shows that resistance accumulated gradually. If antibiotic use had been more careful—less routine, more targeted—the pressure on the bacterium to evolve might have been lower. But that's speculative. What we know is that by 2005, the moment had largely passed. The dominant strain was already established.
What happens if this bacterium keeps evolving?
Infections become untreatable. We have fewer and fewer drugs that work against it. For vulnerable patients in hospitals, that means infections that can't be cured. The bacterium doesn't kill you directly—your own immune system can't fight it, and we have no weapons left. That's the scenario everyone in medicine is trying to prevent.